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 Sophoraflavanone G (SG), a natural compound isolated from S. alopecuroides  
 SG exhibits synergetic effect with norfloxacin against SA1199B in vitro and vivo 
 NorA Efflux pump inhibition contributes to the synergistic effects of SG  
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Staphylococcus aureus including methicillin resistant variants (MRSA) is still a challeng in the 
clinical and community settings. The design and discovery of new compounds to deal with resistant 
bacteria has become one of the most important areas of antiinfective research today. The goal of 
         
this study was to address the problem of MRSA by searching for synergistic antibacterial natural 
products fromtraditional Chinese herbs that are not substrates for the efflux mechanisms of MRSA 
strains and that overcome drug-resistance of bacteria by other, as yet, undescribed mechanisms. In 
vitro, synergistic activity was determined using the standard checkerboard method, and mechanistic 
studies were performed by an ethidium bromide (EtBr) efflux assay. Using in vivo experiments, the 
efficacies of different concentrations of the combinations were compared in a murine model of 
pyaemia. The natural product sophoraflavanone G (SG) showed specific synergistic antibacterial 
effects both in vitro and in vivo and may serve as a template for agents with antibiotic-potentiating 
activity for use against infections caused by S. aureus. 
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1 Introduction 
Antibiotics have played a vital role in saving the lives of infected individuals and have contributed 
to major gains in life expectancy over the last century [1]. However, the widespread and 
inappropriate use of antibiotics has resulted in the worldwide emergence of antimicrobial resistance 
(AMR) [2]. Currently, there are 15 drug-resistant microorganisms classified as “urgent” or 
“serious” by the US Center for Disease Control Prevention (CDC), which includes 
methicillin-resistant Staphylococcus aureus (MRSA) [3]. The limited therapeutic options for 
infections caused by MRSA and effluxing variants may lead to higher mortality rates and costs than 
those caused by susceptible staphylococci [4]. Researchers are becoming increasingly interested in 
natural products, which may not be substrates for the mechanisms of drug resistance inbacteria. 
Some natural products show direct antibacterial activities, whilst others demonstrate synergistic 
activity [5,6]. Synergy is a widely recognized pharmacological phenomenon and could be utilized 
to identify new pharmaceuticals [7]. This could offer an alternative strategy to overcome 
drug-resistance. 
Bacteria have four common mechanisms to acquire antibiotic resistance. Among these, 
multidrug-resistance (MDR)-related effluxis important and has been reported for many organisms 
[8,9]. Different MDR transporters such as QacA and NorA have been known as resistance 
mechanisms in S. aureus for some time [10,11].  
In our current study, an extraction of the Traditional Chinese medicinal herb Sophora 
alopecuroides L. was prepared using alcohol and analysed in broth microtitre plate checkerboard 
assays in combination with the antibiotics. Tracing the positive synergistic results of the extract 
         
against growth inhibition for the resistant S. aureus strains, we gradually focused the 
synergistically-active fraction by successive chromatographic analyses. 
We finally isolated the dihydroflavonoid sophoraflavanone G (SG), which has previously been 
reported to have anti-MRSA activity [12]. We studied the inhibition effects of SG on five different 
types of MRSA strains from different genetic background (SA1199B, XU212, RN4220, 
EMRSA-15 and EMRSA-16) combined with different antibiotics, but it only showed synergistic 
effects with norfloxacin against strain SA1199B. The S. aureus strain SA1199B, which exhibits 
norfloxacin resistance through increased expression of the NorA-efflux protein [13]. Using strain 
SA1199B, we evaluated the synergistic effects of SG combined with norfloxacin in vitro using the 
broth microdilution method [14] and in vivo in a murine model of pyaemia [15]. The mechanism of 
synergy was then studied using an efflux inhibition assay with EtBr as efflux substrate. 
2 Materials and methods 
2.1 Bacterial strain and antimicrobial agents 
The S. aureus strain SA1199B used for both in vitro and in vivo studies, which overexpresses the 
norA gene encoding the NorA efflux protein, was the generous gift of Professor Glenn W. Kaatz 
[16]. The antibiotic norfloxacin was purchased from Dalian Meilun Biology Technology Co. Ltd. 
(China). Sophoraflavanone G, the NMR data for which ispresented in Supplementary Table S1 and 
the structure is shown in Fig.1, was isolated and purified from the extract of Sophora alopecuroides 
L., with a purity of 99% observed using an HPLC-UV detector (Supplementary Fig. S1). 
2.2 In vitro synergy tests  
         
Broth microdilution antimicrobial checkerboard assays were performed to examine the presence of 
a synergistic interaction [17]. SG was tested in combination with norfloxacin against SA1199B at 
concentration ranges of 0.125-8 and 0.125-64 mg/L, respectively. All of the treatments were tested 
in duplicate wells. The effect of the combination of SG with norfloxacin was evaluated by 
calculating the fractional inhibitory concentration index (FICI) according to theformula: 
FICI = 
                                      
                      
 + 
                                      
                    
 
“Synergistic” effects were defined as when the FICI was less than or equal to 0.5; an“indifference” 
effect was defined as when the FICI was greater than 0.5 and less than or equal to 4.0; and an 
“antagonistic” effect was observed when the FICI was greater than 4.0 [18].  
2.3 EtBr efflux assay 
Considering that the test strain SA1199B overexpresses the NorA efflux pump, we postulated 
that the synergistic effect results from inhibition of the NorA efflux pump, for which 
norfloxacin is a substrate. To determine the mechanism of the interaction between SG and 
norfloxacin, an efflux assay was performed as previously described [19] (See Supplementary 
Material). 
2.4 In vivo synergy tests 
An in vivo infection assay was performed according to a previously reported method with some 
modifications [20]. Six groups of ten female ICR mice (each weighing 18-22 g; Shanghai Sippr-BK 
Laboratory Animal Co.Ltd.) were used in the study (See Supplementary Material). 
3 Results 
         
SG showed significant synergistic effects when combined with norfloxacin against strain SA1199B, 
resulting in a 16-fold reduction in the MIC of norfloxacin against SA1199B, from 32 to 2 mg/L. 
The minimum inhibitory concentration (MIC) of SG and norfloxacin were 4 and 32 mg/L 
respectively. The FICI value of the combination was 0.188. The results suggest that SG has notable 
synergistic activity towards the drug-resistant strain SA1199B. 
Whilst SG showed no inhibitory effects alone at the concentrations tested, it had a strong „efflux 
pump inhibitory‟ effects against SA1199B. Within the first half hour of the assay, SG showed 
competitive efflux pump inhibitory effects compared with the positive control CCCP, whereas this 
effect was weaker compared with that observed for CCCP over the subsequent half hour (Fig. 2). 
To examine the in vivo synergistic effects between SG and norfloxacin, mice were administered 
(i.v.) with 10
6
 CFU/mL of SA1199B and monitored for 7 consecutive days. As shown in Fig. 3, the 
mice in the vehicle group died within 12 h after infection, whereas six mice in the group treated 
with SG (180 mg/kg) alone group died within 12 h, and all died within 24 h. In the group treated 
with norfloxacin (180 mg/kg) alone, a weak effect was observed on the survival rate of the infected 
mice, where six mice died within 7 days. The three groups of mice with the same dose of SG (100 
mg/kg) and different doses of norfloxacin (60, 90 and 120 mg/kg; the synergism groups) had 
survival rates of 40, 50 and 70% respectively. These data showed thatat a dose of 100 mg/kg, SG 
synergistically increased the antibacterial activity of norfloxacin in vivo in a dose-dependent manner 
(Fig. 3). 
4 Discussion 
Sophoraflavanone G (SG), isolated and purified from the traditional Chinese medicine 
Sophora alopecuroides, showed a significant synergistic effect together with the classical antibiotic 
         
norfloxacin at a low concentration (1 mg/mL) against the fluoroquinolone-resistant strain SA1199B 
in vitro. The MIC of norfloxacin combined with SG was sixteen times less than that of norfloxacin 
alone, which resulted in an FICI value of 0.188, less than the synergy evaluation threshold of 0.5.  
Considering that SA1199B overexpresses the NorA efflux protein, we postulated that the 
synergistic mechanism of the interaction between SG and norfloxacin was efflux pump inhibition. 
The results of the EtBr efflux assayssupported this postulation. The natural product SG showed a 
similar efflux pump inhibitory activity on SA1199B compared to the positive control (CCCP), and 
they both showed a significant difference compared with the vehicle in the EtBr efflux assay (Fig. 
2). 
Whilst SG has been previously described and there are some reports ofits antibacterial effects, 
there are no reports describing its synergistic activities on drug-resistant strains in vivo. As we were 
able to observe an in vitro synergistic effect with norfloxacin, we performed an in vivo test in mice 
and observed a positive effect. A synergistic effect between SG (100 mg/kg, p.o.) and norfloxacin 
against SA1199B infection was observed, which increased the survival of mice at 7 days after 
infectionina dose-dependent manner (Fig. 3). The same survival rate was observed for mice treated 
with norfloxacin alone (180 mg/kg) and those treated with a combination of SG (100 mg/kg, 
ineffective dose alone) and norfloxacin (60 mg/kg), yielding the same effect on mouse survival with 
a dosage of norfloxacin that was decreased by 2/3 compared to the treatment with norfloxacin 
alone. The survival rate observed usinga combination of SG (100 mg/kg, ineffective dose alone) 
and norfloxacin (120 mg/kg) was much higher than that observed for norfloxacin alone (180 
mg/kg). But the statistical analysis result between synergism group (SG 100 mg/kg + norfloxacin 
         
120 mg/kg) and norfloxacin alone group (180 mg/kg) showed no statistical difference (p<0.17) and 
this maybe due to individual difference or too few samples used for statistical analysis. 
5 Conclusion 
The results of this study show that sophoraflavanone G exhibits synergistic antibacterial effects 
against SA1199B by inhibiting the NorA efflux pump in this norfloxacin-resistant strain. Recently, 
norfloxacin has been shown to exhibit a series of serious side-effects and toxicity during its clinical 
use [20]. However, it is an inexpensive and useful antibiotic against many types of bacteria. The 
synergy with a non-toxic compound may reduce the dose of norfloxacin required for its 
antibacterial efficacy, thereby avoiding some side-effects. Furthermore, by improving the solubility 
and pharmacokinetic parameters as well asenhancing the synergistic effects, a compound such as 
SG may be a potential drug-lead for treating infections by effluxing bacteria. 
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Legends of Figures 
 
Figure 1. Chemicaltructure of SG isolated from Sophora alopecuroides. 
         
 
 
Figure 2. EtBr efflux inhibitory effects of SG against S. aureus SA1199B. 
SA1199B was treated with SG (1 mg/L, 1/4 MIC), the known efflux inhibitor CCCP (100 µmol/L) 











Figure 3. Survival curves of combinations of SG and norfloxacin for SA1199B-infected mice. 
Mice were administered PBS (vehicle), SG (180 mg/kg) alone, norfloxacin (180 mg/kg) alone, or 
combinations of SG (100 mg/kg) and norfloxacin (60, 90 and 120 mg/kg). The survival of all groups 
was monitored at 12-h intervals for 7 consecutive days. 
         
